Last updated: October 24, 2026
Zyrtec is the consumer brand for cetirizine hydrochloride, a second-generation antihistamine used for allergic rhinitis and chronic urticaria. Its prescription-era exclusivity ended before the product became an established over-the-counter brand in the United States. The current market is largely generic and retail-driven, with Kenvue owning the U.S. Zyrtec brand following Johnson & Johnson’s consumer-health separation.
Zyrtec’s commercial trajectory has four phases:
- Prescription launch and rapid adoption in the 1990s.
- Patent and regulatory exclusivity erosion in the mid-2000s.
- U.S. prescription-to-OTC conversion in 2007.
- Mature OTC competition against Claritin, Allegra, store brands and online retailers.
The product has no meaningful biosimilar exposure. Its principal risks are private-label substitution, retailer bargaining power, price competition and category switching.
What is Zyrtec and who owns the brand?
Zyrtec contains cetirizine hydrochloride, an oral H1 antihistamine. It is marketed for temporary relief of symptoms associated with hay fever and other respiratory allergies, including sneezing, runny nose, itchy or watery eyes and nasal or throat itching. It is also used for chronic hives under FDA-approved labeling.[1]
The brand’s ownership and commercialization history is more complex than the current retail shelf suggests.
| Period |
Commercial development |
Principal company |
| 1980s-1990s |
Cetirizine developed and commercialized through UCB licensing arrangements |
UCB and regional licensees |
| 1995 |
U.S. prescription approval for Zyrtec |
Pfizer |
| 2006 |
Pfizer Consumer Healthcare acquired by Johnson & Johnson |
Johnson & Johnson |
| 2007 |
U.S. prescription-to-OTC switch |
Johnson & Johnson/McNeil |
| 2023 |
Johnson & Johnson consumer-health separation completed |
Kenvue |
Kenvue’s portfolio includes Zyrtec, Tylenol, Motrin, Neutrogena and other consumer-health brands. Kenvue’s annual reporting groups products into operating categories and does not consistently disclose standalone Zyrtec revenue.[2]
What patents protected Zyrtec?
The principal U.S. patent associated with cetirizine was U.S. Patent No. 4,525,358, covering piperazine derivatives and related antihistamine compounds. The patent was assigned to UCB-related interests and supported the original cetirizine product franchise.[3]
Key Zyrtec patent and exclusivity data
| Item |
Data |
| Active ingredient |
Cetirizine hydrochloride |
| Original U.S. product |
Zyrtec |
| Original U.S. prescription approval |
December 1995 |
| Principal compound patent |
U.S. Patent No. 4,525,358 |
| Regulatory pathway |
New drug application |
| U.S. prescription market |
1995-2007 |
| U.S. OTC switch |
2007 |
| Current protection |
Brand, trademark, formulation and commercial execution rather than core molecule exclusivity |
The timing of market entry reflected the interaction between the patent term, regulatory review, pediatric exclusivity and the prescription-to-OTC transition. By 2007, the core molecule no longer provided a durable barrier to generic cetirizine.
The original product patent did not create a meaningful long-term barrier after the OTC switch. Current Zyrtec economics depend on brand recognition, distribution, shelf placement, advertising, consumer familiarity and retailer relationships.
When did Zyrtec lose exclusivity?
Zyrtec lost practical prescription-market exclusivity in 2007, when FDA-approved generic cetirizine products entered the U.S. market and the branded product moved to OTC status.[1][4]
The transition had two effects:
- Prescription revenue faced direct generic substitution.
- Consumer access expanded through mass-market retail channels, supporting a much larger but lower-priced market.
The 2007 switch was commercially important because it changed Zyrtec from a physician-prescribed medicine into a high-volume consumer brand. OTC conversion can increase unit volume while reducing average price and weakening the originator’s ability to capture prescription-level margins.
What is the FDA and Orange Book status of Zyrtec?
Zyrtec originated as an FDA-approved prescription drug and later became an OTC product through an FDA-approved switch. The current retail products are regulated under OTC monograph and product-specific labeling frameworks, depending on dosage form and presentation.
The historical prescription product was listed in FDA’s Orange Book under cetirizine-related product information. Orange Book relevance is now limited because the core drug is generic and the principal U.S. Zyrtec business is OTC.[1]
FDA milestones
| Date |
Event |
| 1995 |
FDA approval of prescription Zyrtec |
| 2000s |
Generic cetirizine products begin entering the U.S. prescription market |
| 2007 |
FDA authorizes OTC marketing of cetirizine products |
| 2007 onward |
Zyrtec competes as an OTC brand against generic and store-brand cetirizine |
The original prescription NDA and subsequent OTC filings should be distinguished from current generic abbreviated new drug applications. Generic cetirizine manufacturers do not need to reproduce the Zyrtec brand or its consumer packaging. They must demonstrate pharmaceutical equivalence and meet FDA quality requirements.
How many patents currently cover Zyrtec?
No core composition-of-matter patent currently provides meaningful exclusivity for cetirizine in the U.S. The commercial brand may be supported by trademarks, packaging rights, product-specific claims and formulation know-how, but those rights do not prevent generic cetirizine competition.
What formulations are protected by Zyrtec patents?
Zyrtec has been sold in several consumer presentations, including:
- 5 mg and 10 mg tablets.
- Chewable tablets.
- Oral syrup or solution for children.
- Dissolving or orally disintegrating products.
- Combination products in selected markets.
These dosage forms can create formulation and product-design differences, but they generally do not recreate the exclusivity of a new molecular entity. A generic manufacturer can compete with a tablet while avoiding a branded dissolving formulation, or can develop an equivalent dosage form after satisfying FDA requirements.
The principal barriers are therefore commercial rather than patent-based. Zyrtec’s brand owner must defend price, shelf space and consumer preference rather than rely on a blocking patent.
Are there Paragraph IV challenges to Zyrtec?
Paragraph IV litigation was relevant to the prescription product before and during generic entry. Under the Hatch-Waxman framework, a generic applicant can certify that listed patents are invalid, unenforceable or not infringed. Such a filing can trigger patent litigation and a potential 30-month stay of FDA approval.
Zyrtec’s principal patent barrier was effectively exhausted by the time generic cetirizine became widely available in 2007. There is no current high-value Paragraph IV dispute comparable to the litigation surrounding patented specialty drugs or biologics.
| Issue |
Current assessment |
| Core molecule patent |
Expired |
| Active prescription exclusivity |
None |
| Current Paragraph IV threat |
Low commercial relevance |
| Generic substitution |
Established |
| Litigation value |
Concentrated in historical disputes, not current exclusivity |
What patent litigation affects Zyrtec?
Zyrtec is not currently associated with a major U.S. patent litigation campaign that threatens the OTC franchise. Historical disputes centered on generic entry and the scope or duration of cetirizine-related patent rights.
Current legal exposure is more likely to involve:
- Trademark infringement.
- False or misleading advertising claims.
- Packaging and trade dress.
- Retail distribution agreements.
- Product liability.
- Regulatory compliance.
- Digital advertising and comparative claims.
These issues can affect marketing cost and brand reputation, but they do not restore exclusivity for cetirizine.
How strong is the Zyrtec patent estate?
The current Zyrtec patent estate is weak as a market-exclusion tool but valuable as part of a mature consumer brand.
| Factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Method-of-use protection |
No material current barrier |
| Formulation protection |
Limited and product-specific |
| Trademark strength |
High |
| Generic entry barrier |
Very low |
| Retail recognition |
High |
| Pricing power |
Moderate to low |
| Regulatory complexity |
Low relative to prescription specialty drugs |
Zyrtec’s strongest assets are brand awareness and distribution. Its weakest assets are patent duration and generic defense.
How has Zyrtec’s financial trajectory changed?
Zyrtec’s financial profile shifted from a high-margin prescription medicine to a high-volume OTC consumer-health product.
Prescription phase
During the 1990s and early 2000s, Zyrtec benefited from:
- Prescription reimbursement.
- Physician prescribing.
- Limited direct substitution before generic entry.
- Premium pricing for a second-generation antihistamine.
- Expansion of the allergy-treatment market.
The product generated substantial value for its originator and licensees during this period, but reported revenue varied by geography, licensing structure and accounting treatment.
Generic-entry phase
Generic cetirizine reduced prescription pricing power. Pharmacy substitution redirected volume away from the branded product, while payers and physicians gained lower-cost alternatives.
The commercial impact followed the standard mature-drug pattern:
- Brand prescription volume declines.
- Generic unit volume increases.
- Average selling price falls.
- Manufacturer margins compress.
- Marketing shifts from physician promotion to consumer advertising.
OTC phase
The 2007 OTC switch expanded distribution through grocery stores, pharmacies, mass merchants and online retailers. The product gained a broader consumer base but competed at lower retail prices.
OTC economics depend on:
- Seasonal allergy intensity.
- Household penetration.
- Advertising efficiency.
- Retailer promotion.
- Private-label pricing.
- Pack size and dosage form.
- Inventory timing.
- E-commerce search placement.
Kenvue reports Zyrtec within broader consumer-health categories rather than as a consistently separate revenue line. This prevents a precise current standalone revenue calculation from public filings.[2]
What is the current Zyrtec market size and revenue exposure?
The U.S. allergy market is large, mature and highly competitive. It includes oral antihistamines, nasal corticosteroids, eye drops, decongestants and combination products. Zyrtec competes primarily in the oral second-generation antihistamine segment.
The largest commercial competitors include:
| Brand |
Active ingredient |
Owner or principal marketer |
Competitive position |
| Zyrtec |
Cetirizine |
Kenvue |
Strong brand in oral antihistamines |
| Claritin |
Loratadine |
Bayer |
Major non-drowsy allergy brand |
| Allegra |
Fexofenadine |
Sanofi |
Major oral antihistamine brand |
| Xyzal |
Levocetirizine |
Opella/Sanofi in selected markets |
Closely related cetirizine-class product |
| Store brands |
Cetirizine, loratadine or fexofenadine |
Retailers and contract manufacturers |
Low-price substitution |
Zyrtec has meaningful revenue exposure to seasonal demand. A weak allergy season, retailer destocking or a shift toward lower-cost private labels can reduce brand sales without any change in clinical demand.
Kenvue’s publicly reported financial results provide company-level and segment-level information, but standalone Zyrtec revenue is not generally reported. Financial analysis should therefore avoid treating total Kenvue Self Care revenue as Zyrtec revenue.[2]
Which companies are challenging Zyrtec commercially?
The main challengers are generic manufacturers and competing consumer-health companies, not patent litigants.
Generic challengers
Generic cetirizine is available from multiple manufacturers. Competition occurs through:
- Pharmacy substitution.
- Retailer-controlled private labels.
- Wholesale acquisition cost.
- Contract manufacturing.
- Online marketplace pricing.
- Multi-pack discounts.
Branded challengers
Claritin and Allegra compete directly for the same allergy consumer. Their differentiation depends on perceived duration, sedation profile, onset, price and advertising.
Retailer challengers
Retail chains and online platforms have increased private-label penetration. A retailer can place store-brand cetirizine next to Zyrtec and price it substantially below the national brand. This limits the ability to raise shelf prices even when the brand retains consumer recognition.
What generic entry risks exist for Zyrtec?
Generic entry is no longer a future risk. It is an established structural condition.
The major risks are:
- Continued conversion from branded Zyrtec to private-label cetirizine.
- Retailer promotion of store brands.
- Consumer switching during inflationary periods.
- E-commerce price transparency.
- Reduced physician influence after OTC conversion.
- Advertising inefficiency in a mature category.
- Formulation imitation by competing OTC products.
Zyrtec can preserve a premium only when consumers value the brand, packaging, perceived reliability or a specific dosage form enough to justify the price difference.
Does Zyrtec face biosimilar risk?
No. Zyrtec is a chemically synthesized small-molecule drug, not a biologic. Biosimilar regulation does not apply.
Its competitive risk is generic substitution under the abbreviated new drug application pathway. That pathway is less costly and less complex than biosimilar development, which contributes to the broad availability of low-cost cetirizine.
What licensing deals shaped Zyrtec?
UCB developed and commercialized cetirizine through licensing and regional commercialization arrangements. Pfizer commercialized Zyrtec in the United States before Pfizer Consumer Healthcare was acquired by Johnson & Johnson in 2006. Johnson & Johnson later transferred the consumer-health business to Kenvue through the 2023 separation.[2]
These transactions changed the brand owner and reporting structure but did not extend the underlying cetirizine patent term.
| Transaction |
Strategic effect |
| UCB-Pfizer commercialization arrangement |
Enabled large-scale U.S. commercialization |
| Pfizer Consumer Healthcare sale to Johnson & Johnson |
Moved Zyrtec into a broader consumer-health portfolio |
| Johnson & Johnson-Kenvue separation |
Established Kenvue as the current consumer-health owner |
How does Zyrtec compare with Claritin and Allegra?
| Metric |
Zyrtec |
Claritin |
Allegra |
| Active ingredient |
Cetirizine |
Loratadine |
Fexofenadine |
| Drug class |
Second-generation antihistamine |
Second-generation antihistamine |
Second-generation antihistamine |
| Prescription exclusivity |
Expired |
Expired |
Expired |
| Current channel |
OTC |
OTC |
OTC |
| Generic availability |
Broad |
Broad |
Broad |
| Primary risk |
Private-label substitution |
Private-label substitution |
Private-label substitution |
| Brand owner |
Kenvue |
Bayer |
Sanofi/Opella structures by market |
| Biosimilar risk |
None |
None |
None |
Zyrtec is often positioned around strong symptom relief and rapid onset, while Claritin emphasizes non-drowsy use and Allegra emphasizes long-lasting relief. These are marketing and consumer-perception distinctions, not patent-based barriers.
What generic launch scenarios exist for Zyrtec?
The relevant generic launch scenario has already occurred. Future market changes are more likely to involve shifts in market share than a single major launch event.
Base case
Zyrtec remains a leading national brand while generic and private-label cetirizine capture most unit volume. Kenvue maintains premium pricing on selected pack sizes and dosage forms.
Downside case
Retailers increase private-label shelf space, consumers trade down and promotional spending rises. Zyrtec revenue declines faster than the overall allergy category.
Upside case
A severe allergy season, effective advertising, product innovation or strong e-commerce placement increases branded demand. Unit growth may still produce limited revenue growth because promotions and private-label competition constrain pricing.
What geographic coverage does Zyrtec have?
Zyrtec is sold in multiple international markets, but brand ownership, labeling, dosage forms and commercialization partners vary by country. Cetirizine is widely available globally under branded and generic names.
Geographic economics depend on:
- Local prescription-to-OTC status.
- National reimbursement systems.
- Patent and supplementary protection certificate history.
- Pharmacy substitution rules.
- Retail concentration.
- Local licensing arrangements.
- Regulatory requirements for pediatric products.
The U.S. is strategically important because of its large OTC market and high retail competition. European markets are more fragmented, with greater variation in pharmacy distribution and brand ownership.
What manufacturing and IP barriers remain?
Manufacturing cetirizine is not generally a high barrier relative to complex biologics, sterile injectables or advanced drug-delivery systems. The active ingredient is a mature small molecule with established manufacturing pathways.
Remaining barriers include:
- FDA and international quality requirements.
- Active-pharmaceutical-ingredient qualification.
- Stability and bioequivalence testing.
- Child-resistant packaging.
- Pediatric formulation controls.
- Supply-chain reliability.
- OTC labeling compliance.
- Retail distribution scale.
These barriers can affect launch timing and quality performance, but they do not prevent well-capitalized generic or private-label manufacturers from competing.
What is the investment outlook for Zyrtec?
Zyrtec is a mature cash-generating consumer brand, not a pipeline asset with meaningful patent-driven growth. Its value rests on brand durability, category demand and Kenvue’s ability to manage price, advertising and distribution.
Key investment variables are:
- Brand share versus Claritin, Allegra and private labels.
- Kenvue’s Self Care performance.
- Gross-margin trends.
- Advertising and promotion intensity.
- Retailer concentration.
- U.S. allergy-season severity.
- International brand performance.
- Consumer trade-down behavior.
- Product innovation and pack architecture.
The absence of current composition-of-matter protection limits legal downside protection. The brand can remain profitable for many years, but the business is exposed to the normal erosion pattern of mature OTC products.
Key Takeaways
- Zyrtec is the cetirizine brand owned by Kenvue in the United States.
- Its principal U.S. patent protection expired before or around its 2007 OTC transition.
- Generic cetirizine has been established in the market for years.
- Current value comes from branding, retail distribution and consumer recognition, not molecule exclusivity.
- Zyrtec faces no biosimilar risk.
- The main competitors are Claritin, Allegra, Xyzal, generic cetirizine and retailer private labels.
- Kenvue does not generally disclose standalone Zyrtec revenue, so precise current brand sales cannot be derived from public financial statements.
- Future performance will depend more on market share, pricing and advertising efficiency than on patent litigation.
FAQs
Is Zyrtec still patented?
The core cetirizine patent protection has expired. Current Zyrtec differentiation comes primarily from trademarks, packaging, formulation execution and brand equity.
Is generic cetirizine the same as Zyrtec?
Generic cetirizine contains the same active ingredient and must satisfy FDA requirements for pharmaceutical equivalence. Inactive ingredients, packaging and branding can differ.
Who manufactures Zyrtec now?
Kenvue owns and markets the U.S. Zyrtec consumer brand. Manufacturing may be performed through a combination of company facilities and qualified third-party suppliers.
Does Zyrtec have an authorized generic?
The U.S. cetirizine market includes multiple generic products. Whether a particular product is an authorized generic depends on the manufacturer and product listing; the broad market does not depend on a branded authorized-generic strategy.
Is Zyrtec a growth or value pharmaceutical asset?
Zyrtec is a mature consumer-health value asset. It can generate durable cash flow but has limited patent-driven growth and substantial exposure to generic substitution, private-label competition and retail pricing pressure.
References
-
U.S. Food and Drug Administration. (2007). FDA approves over-the-counter cetirizine for allergy relief. FDA.
-
Kenvue Inc. (2024). Annual report for the fiscal year ended December 31, 2023. Kenvue Inc.
-
U.S. Patent and Trademark Office. (1985). U.S. Patent No. 4,525,358: Piperazine derivatives. U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
